prikaz prve stranice dokumenta Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
  Download
PDF 452.25 KB
Scientific paper - Case study
Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
Monaldi Archives for Chest Disease, 89 (2019), 2; https://doi.org/10.4081/monaldi.2019.1023
Hećimović, Ana; Vukić Dugac, Andrea; Janković Makek, Mateja; Čikeš, Maja; Samaržija, Miroslav; Jakopović, Marko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Hećimović, A., Vukić Dugac, A., Janković Makek, M., Čikeš, M., Samaržija, M. & Jakopović, M. (2019). Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient. Monaldi Archives for Chest Disease, 89. (2). doi: 10.4081/monaldi.2019.1023

Hećimović, Ana, et al. "Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient." Monaldi Archives for Chest Disease, vol. 89, no. 2, 2019. https://doi.org/10.4081/monaldi.2019.1023

Hećimović, Ana, Andrea Vukić Dugac, Mateja Janković Makek, Maja Čikeš, Miroslav Samaržija and Marko Jakopović. "Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient." Monaldi Archives for Chest Disease 89, no. 2 (2019). https://doi.org/10.4081/monaldi.2019.1023

Hećimović, A., et al. (2019) 'Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient', Monaldi Archives for Chest Disease, 89(2). doi: 10.4081/monaldi.2019.1023

Hećimović A, Vukić Dugac A, Janković Makek M, Čikeš M, Samaržija M, Jakopović M. Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient. Monaldi Archives for Chest Disease [Internet]. 2019 May 30 [cited 2024 November 25];89(2). doi: 10.4081/monaldi.2019.1023

A. Hećimović, A. Vukić Dugac, M. Janković Makek, M. Čikeš, M. Samaržija and M. Jakopović, "Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient", Monaldi Archives for Chest Disease, vol. 89, no. 2, May 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:233301. [Accessed: 25 November 2024]

Metadata
Title (english)Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
AuthorAna Hećimović
AuthorAndrea Vukić Dugac
AuthorMateja Janković Makek
AuthorMaja Čikeš
AuthorMiroslav Samaržija
AuthorMarko Jakopović
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Lung cancer incidence in heart transplant patients is higher than in general population and correlates with smoking history. EGFR-mutations are more frequent in adenocarcinoma and among non-smoking women but incidence in solid organ transplanted patients is still not known. We present case of a 65-yearold ex-smoker male with history of heart transplantation and EGFR positive metastatic lung adenocarcinoma. At admission he was in a severe clinical condition and treatment with erlotinib was started. Initially he had good clinical and radiologic response to treatment with only grade 1 side effects. Data about drug interactions between cyclosporine and erlotinib are insufficient but we have to take this interaction into consideration during treatment because both drugs are substrates and inhibitors of CYP34A. In our case erlotinib was safe and well tolerated drug, there were no relevant toxicity, but close monitoring and dose reduction of cyclosporine was needed.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMonaldi Archives for Chest Disease
Numberingvol. 89, no. 2
p-ISSN1122-0643
DOIhttps://doi.org/10.4081/monaldi.2019.1023
URN:NBNurn:nbn:hr:105:233301
Publication2019-05-30
Document URLhttp://doi.org/10.4081/monaldi.2019.1023
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 10:32:48